IDXX Q3 Earnings & Revenues Surpass Estimates, Stock Up in Pre-Market
IDEXX Laboratories reported Q3 2026 EPS of $4.01, up 18% YoY, and revenue of $1.21B, up 10% YoY, both exceeding estimates. CAG Diagnostics drove growth, with revenues up 10.2%. Margins expanded despite higher expenses. IDXX raised 2026 guidance, now expecting $4.74B-$4.77B in revenue and $14.96-$15.16 in EPS. Shares gained 5.2% in pre-market trading.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift provide fresh actionable information for traders, with the stock already up 5.2% pre‑market.
Market read
Earnings beat and guidance raise are primary catalysts that can drive short‑term price moves and influence sector sentiment.
What to watch
Higher operating expenses and acquisition costs could pressure margins if growth slows.
Background
IDEXX Laboratories reported Q3 2026 results, beating EPS and revenue estimates and raised its full‑year outlook.
Ticker impact
Q3 2026 earnings beat estimates and raised 2026 revenue and earnings guidance, prompting a 5.2% pre‑market share gain.
likely upward pressure as investors price in higher revenue and earnings outlook
Earnings beat and guidance lift are fresh primary disclosures; market already reacted positively pre‑market.
Market effects
Strengthens the veterinary diagnostics sector, may lift peers such as ISRG and MEDP.
Positive for U.S. healthcare stocks in the broader market.
Limited to healthcare/diagnostics niche, no broad macro effect.
Counterpoint
If guidance is overly optimistic, future earnings could miss, leading to a pull‑back.
Key entities
- companyIDEXX Laboratories
Veterinary diagnostics firm reporting Q3 earnings and raising guidance.
